AR063415A1 - Hidratos de clorhidrato de erlotinib para el tratamiento del cancer - Google Patents

Hidratos de clorhidrato de erlotinib para el tratamiento del cancer

Info

Publication number
AR063415A1
AR063415A1 ARP070104756A ARP070104756A AR063415A1 AR 063415 A1 AR063415 A1 AR 063415A1 AR P070104756 A ARP070104756 A AR P070104756A AR P070104756 A ARP070104756 A AR P070104756A AR 063415 A1 AR063415 A1 AR 063415A1
Authority
AR
Argentina
Prior art keywords
erlotinib
peaks
chlorhydrate
hydrates
cancer treatment
Prior art date
Application number
ARP070104756A
Other languages
English (en)
Inventor
Raymond Jozef Hubertus Westheim
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR063415A1 publication Critical patent/AR063415A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se refiere a un hidrato de clorhidrato de erlotinib cristalino y a un proceso para preparar anhidrato de erlotinib cristalino, que comprende cristalizar un hidrato de clorhidrato de erlotinib a partir de una solucion acuosa de clorhidrato de erlotinib; y recristalizar dicho hidrato de clorhidrato de erlotinib a partir de un sistema solvente no acuoso para formar un clorhidrato de erlotinib anhidro de la forma A, forma B, o forma E. Reivindicacion 3: El hemihidrato de acuerdo con la reivindicacion 2, el cual es la forma 1 caracterizado por picos de XRPD a 2theta de 5,8, 9,4, 10,0, 11,1, 11,6, 17,5, 18,6, 24,9 y 26,8 +/- 0,2 grados, y/o picos de FT-IR a 900, 950, 1152, 1216, 1484, 3254, 3327 y 3382 +/- 4 cm-1. Reivindicacion 5: Un hidrato de acuerdo con la reivindicacion 2, el cual es la forma 2, caracterizado por picos de XRPD a 2theta de 5,8, 10,6, 12,1, 14,6, 15,1, 17,3, 19,3, 24,3 y 26,3, +/- 0,2 grados, y/o picos de FT-IR a 649, 867, 901, 948, 1029, 1073, 1213, 1242, 1355, 1431, 1484, 1624 y 3401 +/- 4 cm-1
ARP070104756A 2006-10-27 2007-10-26 Hidratos de clorhidrato de erlotinib para el tratamiento del cancer AR063415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86315806P 2006-10-27 2006-10-27

Publications (1)

Publication Number Publication Date
AR063415A1 true AR063415A1 (es) 2009-01-28

Family

ID=39251354

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104756A AR063415A1 (es) 2006-10-27 2007-10-26 Hidratos de clorhidrato de erlotinib para el tratamiento del cancer

Country Status (5)

Country Link
US (1) US8372856B2 (es)
EP (1) EP2099772A2 (es)
AR (1) AR063415A1 (es)
CL (1) CL2007003089A1 (es)
WO (1) WO2008049645A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389531B2 (en) * 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
US20100136116A1 (en) * 2007-08-17 2010-06-03 Hetero Drugs Limited Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
JP5948597B2 (ja) 2010-07-23 2016-07-06 ジェネリクス・［ユーケー］・リミテッド 純粋なエルロチニブ
CN103570634B (zh) * 2012-08-10 2018-01-26 上海创诺医药集团有限公司 盐酸埃罗替尼多晶型物及其制备方法
WO2014023027A1 (zh) * 2012-08-10 2014-02-13 上海创诺医药集团有限公司 盐酸埃罗替尼多晶型物及其制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN106749048B (zh) * 2017-01-14 2020-03-20 山东裕欣药业有限公司 一种盐酸厄洛替尼晶型化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
CA2622136A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer

Also Published As

Publication number Publication date
US20080167327A1 (en) 2008-07-10
WO2008049645A2 (en) 2008-05-02
WO2008049645A3 (en) 2008-07-31
EP2099772A2 (en) 2009-09-16
US8372856B2 (en) 2013-02-12
CL2007003089A1 (es) 2008-05-09

Similar Documents

Publication Publication Date Title
AR063415A1 (es) Hidratos de clorhidrato de erlotinib para el tratamiento del cancer
AR067356A1 (es) Procesos para la preparacion de pirazoles
BR112012020596A8 (pt) substrato para a imobilização de substâncias funcionais e processo para preparar o mesmo.
MY160785A (en) Manufacturing process for pyrimidine derivatives
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
PE20141146A1 (es) Inhibidores de la enzima activadora de nedd8
WO2013014665A8 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
BR112015015097A2 (pt) método para produção de composto de amina purificada
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
AR084864A1 (es) Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso
MA29690B1 (fr) Procede de preparation de la 4beta-amino-4'-demethyl-4-desoxypodophyllotoxine
EA201200498A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
FR2946339B1 (fr) Procede d'hydroxydation de composes amples halogenes
EA200701256A1 (ru) Способ получения высокочистых мелоксикама и калиевой соли мелоксикама
BR112012011786A2 (pt) "método para a produção de derivados de ácido glutâmico marcados por f-18"
FR2921565B1 (fr) Procede de recuperation d'acides fluorocarboxyliques
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
NI200700226A (es) Recuperación de cci-779 a partir de soluciones madre
WO2007083243A3 (en) An improved process for the preparation of risedronate sodium hemi-pentahydrate
IN2013MU01466A (es)
ITMI20051115A1 (it) Procedimento per l'ottenimento di cefotetan con resa elevata
EA200970116A1 (ru) Кристаллический гидрохлорид неморубицина
WO2010036497A3 (en) Selective estrogen repector modulator for the treatment of osteoarthritis
CL2017003172A1 (es) Método para producir cianuro de sodio

Legal Events

Date Code Title Description
FB Suspension of granting procedure